Nathaly Irizarry-Arroyo
Overview
Explore the profile of Nathaly Irizarry-Arroyo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoogland A, Li X, Modi K, Welniak T, Rodriguez Y, Irizarry-Arroyo N, et al.
Transplant Cell Ther
. 2024 Dec;
31(3):157.e1-157.e13.
PMID: 39733840
Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor T-cell therapy, has significantly improved clinical outcomes in adult patients with relapsed/refractory large B-cell lymphoma. However, few studies have examined patient-reported outcomes (PROs)...
2.
Hoogland A, Barata A, Li X, Irizarry-Arroyo N, Jain M, Welniak T, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1219.e1-1219.e11.
PMID: 39306278
Chimeric antigen receptor (CAR) T-cell therapy has transformed survival outcomes in patients with relapsed and refractory large B-cell lymphoma (LBCL), but it is associated with a variety of side effects....
3.
Kirtane K, Reblin M, Oswald L, Irizarry-Arroyo N, McCormick R, Locke F, et al.
Leuk Lymphoma
. 2022 Nov;
64(2):364-370.
PMID: 36416677
Chimeric antigen receptor T-cells and other immunotherapies have markedly changed the paradigm of treatment for patients with relapsed or refractory hematologic malignancies. While notable in efficacy, immunotherapy is characterized by...
4.
Oswald L, Li X, Carvajal R, Hoogland A, Gudenkauf L, Hansen D, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681722
Background: Clinicians must closely monitor patients for toxicities after chimeric antigen receptor T-cell therapy (CAR-T). Patient-reported outcomes (PROs) (e.g., toxicities, quality of life) and activity data (e.g., steps, sleep) may...
5.
Barata A, Hoogland A, Hyland K, Otto A, Kommalapati A, Jayani R, et al.
Psychooncology
. 2021 Mar;
30(8):1294-1301.
PMID: 33739548
Objective: Informal family caregivers provide critical support for patients receiving chimeric antigen receptor (CAR) T-cell therapy. However, caregivers' experiences are largely unstudied. This study examined quality of life (QOL; physical...
6.
Hoogland A, Jayani R, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain M, et al.
Cancer Med
. 2021 Feb;
10(6):1936-1943.
PMID: 33641257
Chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel (axi-cel) has considerably improved survival in adults with relapsed/refractory large B-cell lymphoma. This study reports patient-reported outcomes (PROs) such as quality of...